Simulations Plus Announces Q3 Revenue and Strategic Changes

The latest announcement is out from Simulations Plus ( (SLP) ).

On June 11, 2025, Simulations Plus announced preliminary revenue figures for its third fiscal quarter, expecting between $19 million and $20 million, and updated its full-year revenue guidance to range between $76 million and $80 million. The company is facing market uncertainties impacting its pharmaceutical and biotech clients, leading to budget cuts and project delays. In response, Simulations Plus has reorganized its operations to a functionally driven model and made key leadership appointments to enhance client engagement and sales capabilities, aiming for long-term growth and operational efficiency.

The most recent analyst rating on (SLP) stock is a Buy with a $56.00 price target. To see the full list of analyst forecasts on Simulations Plus stock, see the SLP Stock Forecast page.

Spark’s Take on SLP Stock

According to Spark, TipRanks’ AI Analyst, SLP is a Outperform.

Simulations Plus demonstrates solid financial performance, particularly in revenue growth and balance sheet strength. However, technical analysis indicates bearish signals, and the company’s valuation suggests it may be overvalued. The earnings call reinforces growth potential, but challenges in project initiation and margin compression pose risks.

To see Spark’s full report on SLP stock, click here.

More about Simulations Plus

Simulations Plus, Inc. is a leading provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Their solutions integrate AI/ML, physiologically based pharmacokinetics, biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling, serving pharmaceutical, biotechnology, and regulatory agencies worldwide.

Average Trading Volume: 335,647

Technical Sentiment Signal: Sell

Current Market Cap: $547.4M

For an in-depth examination of SLP stock, go to TipRanks’ Stock Analysis page.